The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BOLT | -53.87% | N/A | N/A | -99% |
| S&P | +16.9% | +95.99% | +14.39% | +75% |
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.80M | 41.5% |
| Gross Profit | $1.46M | 78.1% |
| Gross Margin | 80.76% | 16.6% |
| Market Cap | $11.06M | -61.3% |
| Market Cap / Employee | $0.21M | 0.0% |
| Employees | 52 | -48.0% |
| Net Income | -$8.56M | 59.6% |
| EBITDA | -$8.86M | 52.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.39M | 67.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $21.62M | 36.0% |
| Short Term Debt | $2.56M | -14.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -50.80% | -8.8% |
| Return On Invested Capital | -77.57% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.60M | 40.5% |
| Operating Free Cash Flow | -$9.60M | 40.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.34 | 0.36 | 0.33 | 0.24 | -13.92% |
| Price to Sales | 2.53 | 2.66 | 4.22 | 2.66 | 3.68% |
| Price to Tangible Book Value | 6.89 | 5.69 | 5.36 | 0.24 | -95.70% |
| Enterprise Value to EBITDA | 0.73 | 0.16 | -0.04 | 0.03 | -97.56% |
| Return on Equity | -65.0% | -74.3% | -83.9% | -81.3% | 40.13% |
| Total Debt | $18.18M | $25.21M | $24.71M | $24.18M | 28.01% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
